We’re excited to be at the 3rd Annual Targeted Radiopharmaceuticals (TRP) Summit in San Diego, CA this week! Tomorrow at 12:15pm PT, Josh Apgar, Ph.D., VP, Global Head of ABM Scientific Affairs, will present on "Clinical Pharmacology & Model-Informed Drug Development Insights for Targeted Radiation Therapies." 📅 Date: July 31st 🕛 Time: 12:15pm PT Learn more about the TRP Summit here: https://ow.ly/gcVU50SNht7 #Radiopharmaceuticals #DrugDevelopment #ClinicalPharmacology #MIDD #TRPSummit2024
About us
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
- Website
-
https://www.certara.com
External link for Certara
- Industry
- Business Consulting and Services
- Company size
- 1,001-5,000 employees
- Headquarters
- Radnor, Pennsylvania
- Type
- Public Company
- Specialties
- model-based drug discovery and development, scientific informatics, PK/PD modeling and simulation, PBPK modeling and simulation, trial design, drug development, regulatory writing, quantitative systems pharmacology, clinical pharmacology, quantitative systems toxicology, transparency and disclosure, model-based meta-analysis, regulatory strategy, regulatory publishing, market access, health economics and outcomes research, and real world evidence solutions
Locations
Employees at Certara
Updates
-
Explore the potential of generative AI (Gen AI) to revolutionize drug development. Read Axendia, Inc.'s Market Research Report, "The State of Generative AI in Life Sciences: The Good, The Bad, The Ugly," and gain insights into: - Opportunities for utilizing Gen AI in drug discovery. - Potential roadblocks to overcome. Read more https://ow.ly/xqCY50So8kZ #DrugDiscovery #LifeSciences #MarketResearch #GenerativeAI #GenAI #ArtificialIntelligence #MachineLearning #RegulatoryCompliance #DataPrivacy #DigitalTransformation #PharmaceuticalIndustry #ClinicalTrials #LifeScienceAI #PharmaAI
-
We've been having a great time at #AAIC24! There's still time to connect with Hugo Geerts and Sarah DiBartolo at their posters today. We are happy to discuss how we can support your Alzheimer's Disease program with biosimulation. #QuantitativeSystemsPharmacology #QSP #DrugDevelopment #AlzheimersDisease #AAIC24
-
Missed Honz Slipka's "Disclosure Without Exposure" presentation last week? No worries! He and Anaya Rehman, Senior Transparency Specialist at Certara, will be hosting a RAPS webinar on the same topic on Wednesday, August 7. Don't miss out on this chance to learn how AI can enhance clinical data protection and trial disclosure. 📅 Date: August 7th 🔗 Register here: https://lnkd.in/e9g7_Pfj #RAPS #Webinar #ClinicalData #AI #DataProtection #ClinicalTrials
-
Modeling and simulation approaches, including Quantitative Systems Pharmacology (QSP), can help address challenges in Alzheimer’s Disease drug R&D, such as complex disease mechanisms, patient variability, and clinical trial design. Connect with our experts, Hugo Geerts and Sarah DiBartolo, and view our posters at AAIC 2024 to learn how QSP can help provide deeper understanding of Alzheimer’s Disease and optimize the development of new therapies. Certara's posters at AAIC 2024: - QSP Model for Therapies Targeting Aβ and Tau Pathologies in Alzheimer’s Disease (In collaboration with Biogen) - Exploring biological response profiles to amyloid antibodies in clinical practice using QSP - Towards predicting individual cognitive trajectories in AD using QSP Learn more and register: https://lnkd.in/eHvHWhm3 #QuantitativeSystemsPharmacology #QSP #DrugDevelopment #AlzheimersDisease #AAIC24
-
In a recent Forbes article, Dr. Patrick Smith, President of Drug Development Solutions at Certara and a council member of the Forbes Technology Panel, discusses how pop culture often misrepresents AI’s potential and capabilities. Read the full article here to learn more about the real-world challenges and opportunities of AI: https://ow.ly/2eJv50SKyfp #AI #Technology #Innovation #Certara #ForbesTechCouncil
-
Developing innovative cancer treatments requires cutting-edge tools. Learn how Genmab utilized SEND Explorer, a web-based tool for non-clinical study data analysis, to streamline data analysis and boost research efficiency. Read the full case study: https://lnkd.in/ex8tcqDd #Certara #Genmab #FutureOfPharma #PharmaceuticalInnovation #DrugDevelopment #CancerResearch #DataManagement #SENDStandards #DataDriven #Nonclinical #PharmaceuticalResearch #AntibodyDrugConjugates #ComplexToxicologyData
-
We're still riding high from the incredible experience at the inaugural CERTAINTY conference! It was inspiring to see over 350 leaders from 150 drug development companies come together to exchange knowledge, tackle industry challenges, and explore strategies for successful drug development. We're excited to keep the momentum going with the launch of CERTAINTY Europe and CERTAINTY APAC this fall! Learn more and register for CERTAINTY Europe here: https://lnkd.in/ejDR83h5 Check out what all the hype is about and what you can expect at #CERTAINTY in this short recap reel. Looking forward to pushing the boundaries in drug development! #globalCertainty #CertaintyEurope #CertaintyJapan #CertaintyChina #CertaintyKorea #Certara #CERTAINTY2024 #drugdevelopment
-
Harness the power of PBPK modeling with our consulting expertise! Discover how one client benefited from our PBPK consulting services. With more than 100 years of combined experience, our team is here to guide you through every phase of drug development. Let’s innovate together. https://ow.ly/BUzS50SGoHz #PBPK #Consulting #PharmaInnovation
-
A new guide has been published in ASCPT Journal Family’s CPT: Pharmacometrics & Systems Pharmacology Journal! Titled “𝗔 𝗴𝘂𝗶𝗱𝗲 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗳𝗶𝗹𝗲𝘀 𝗳𝗼𝗿 𝗽𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹𝗹𝘆-𝗯𝗮𝘀𝗲𝗱 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗸𝗶𝗻𝗲𝘁𝗶𝗰 (𝗣𝗕𝗣𝗞) 𝗺𝗼𝗱𝗲𝗹𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗲 𝗦𝗶𝗺𝗰𝘆𝗽 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗼𝗿,” this article is a collaborative effort by Certara contributors and the Centre for Applied Pharmacokinetic Research (CAPKR) at The University of Manchester. https://ow.ly/YLnX50SKpex The guide highlights the use of the Simcyp Simulator, a widely used platform for PBPK modelling and simulation, as part of the credibility assessment framework in model-informed drug development (MIDD). By incorporating tools like Simcyp, the tutorial summarizes the keys factors to be considered when creating a virtual population and highlights the utility of PBPK in understanding the impact in varying populations and how it can be used to answer questions related to specific populations outside of healthy volunteers. Kudos to the brilliant team from Certara: Liam Curry, Frederic Yves Bois, Eman El-Khateeb, Trevor Johnson, Ruth Clayton, Muhammad Faisal, Kris Wragg, Sibylle Neuhoff, and Amin Rostami-Hodjegan. And from the University of Manchester: Sarah Alrubia! View the guide here: https://ow.ly/YLnX50SKpex #Pharmacokinetics #PBPK #Simcyp #MIDD #DrugDevelopment #PharmaResearch #Certara #CAPKR #InnovationInScience